Objectives/Hypothesis. Glucocorticoids (GC) are commonly employed to treat various vocal fold (VF) pathologies. However, VF atrophy has been reported as a potential morbidity associated with intracordal GC injections, and specifically dexamethasone. Dexamethasone-induced atrophy is well-documented in other tissues and putatively thought to be mediated by increased muscle proteolysis via upregulation of Muscle Ring Finger (MuRF)-1 and Atrogin-1. To date, mechanism(s) of dexamethasone-mediated VF atrophy has not been described. We sought to use an established preclinical model to investigate the effects of a single intracordal dexamethasone injection on thyroarytenoid (TA) muscle atrophy. We hypothesized a single intracordal dexamethasone injection will elicit transcriptional changes associated with atrophy and decreased TA muscle fiber size.